Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Long

Showing results (71-80 of 703) with videos related to

Pageof 71
Sort By:
Chest|March 1, 1973
A new myocardial pacemaker lead (sutureless)S W Hunter, L Bolduc, V Long, et al.
Contributions to Microbiology and Immunology|January 1, 1995
Sepsis-enhancing effect of cobalt-60 irradiation in mice infected with virulent Yersinia pestis on the same day or seven days laterA Wake, P V Long, H G Hien, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 6, 2022
Double Trouble: Immunotherapy Doublets in Melanoma-Approved and Novel Combinations to Optimize Treatment in Advanced MelanomaFlorentia Dimitriou, Axel Hauschild, Janice M Mehnert, et al.
The Lancet. Oncology|October 5, 2015
Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trialsJean Jacques Grob, Georgina V Long, Dirk Schadendorf, et al.
Critical Reviews in Oncology/Hematology|September 12, 2015
Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanomaMatteo S Carlino, Georgina V Long, Richard F Kefford, et al.
Melanoma Management|September 8, 2018
Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy?James S Wilmott, Peter Hersey, Georgina V Long, et al.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2016
Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?Sarah J Welsh, Helen Rizos, Richard A Scolyer, et al.
Nature Reviews. Clinical Oncology|April 5, 2017
Targeted agents and immunotherapies: optimizing outcomes in melanomaJason J Luke, Keith T Flaherty, Antoni Ribas, et al.
Pathology|March 30, 2016
Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologistsHojabr Kakavand, James S Wilmott, Georgina V Long, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2017
The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1James S Wilmott, Helen Rizos, Richard A Scolyer, et al.
Pageof 71

Showing results (71-80 of 703) with videos related to

Sort By:
Pageof 71
Chest|March 1, 1973
A new myocardial pacemaker lead (sutureless)S W Hunter, L Bolduc, V Long, et al.
Contributions to Microbiology and Immunology|January 1, 1995
Sepsis-enhancing effect of cobalt-60 irradiation in mice infected with virulent Yersinia pestis on the same day or seven days laterA Wake, P V Long, H G Hien, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 6, 2022
Double Trouble: Immunotherapy Doublets in Melanoma-Approved and Novel Combinations to Optimize Treatment in Advanced MelanomaFlorentia Dimitriou, Axel Hauschild, Janice M Mehnert, et al.
The Lancet. Oncology|October 5, 2015
Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trialsJean Jacques Grob, Georgina V Long, Dirk Schadendorf, et al.
Critical Reviews in Oncology/Hematology|September 12, 2015
Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanomaMatteo S Carlino, Georgina V Long, Richard F Kefford, et al.
Melanoma Management|September 8, 2018
Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy?James S Wilmott, Peter Hersey, Georgina V Long, et al.
European Journal of Cancer (Oxford, England : 1990)|May 28, 2016
Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?Sarah J Welsh, Helen Rizos, Richard A Scolyer, et al.
Nature Reviews. Clinical Oncology|April 5, 2017
Targeted agents and immunotherapies: optimizing outcomes in melanomaJason J Luke, Keith T Flaherty, Antoni Ribas, et al.
Pathology|March 30, 2016
Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologistsHojabr Kakavand, James S Wilmott, Georgina V Long, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2017
The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1James S Wilmott, Helen Rizos, Richard A Scolyer, et al.
Pageof 71